Pricing Log in Create free account

Neumora Therapeutics, Inc. (NMRA) vs Rallybio Corporation (RLYB)

Neumora Therapeutics, Inc. and Rallybio Corporation are both Biotechnology companies. Neumora Therapeutics, Inc. and Rallybio Corporation are of similar size ($90.2M and $90.2M). Neumora Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 2.1×. Across the 11 metrics below, Rallybio Corporation leads on 9 and Neumora Therapeutics, Inc. on 2.

Valuation

Metric NMRA RLYB Biotechnology median
P/E n/m 2.11 8.68
P/S n/m 113.05 10.29
P/B 2.00 1.03 2.40
Price to free cash flow n/m 3.64 20.52
EV/EBITDA n/m n/m 0.68
EV/Sales n/m 4.83 10.15
Earnings yield (256.25%) 47.35% (28.86%)
Free cash flow yield (202.88%) 27.51% (22.44%)

Profitability

Metric NMRA RLYB Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (187.11%) 64.86% (56.66%)
Return on assets (121.89%) 61.12% (49.22%)
Return on invested capital 0.00% (1,052.03%) 0.00%

Growth

Metric NMRA RLYB Biotechnology median
Revenue growth (TTM) — 1.18% 5.64%
EPS growth (last fiscal year) 5.23% 85.06% 30.08%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric NMRA RLYB Biotechnology median
Debt to equity 1.19 0.00 0.00
Current ratio 4.50 27.26 4.72
Net debt to EBITDA 0.53 1.63 0.96

Dividend

Metric NMRA RLYB Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric NMRA RLYB Biotechnology median
Market cap 90.15m 90.23m 150.40m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack